Balance Sheet Information (Tables)
|
3 Months Ended |
Mar. 31, 2023 |
|---|
| Balance Sheet Related Disclosures [Abstract] |
|
| Schedule of of cash and cash equivalents and restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2023 |
|
December 31, 2022 |
| Cash and Cash Equivalents |
$ |
3,426,067 |
|
|
$ |
5,964,556 |
|
| Restricted Cash, Non-current |
4,185 |
|
|
49,260 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
3,430,252 |
|
|
$ |
6,013,816 |
|
|
| Schedule of prepaid expenses and other current assets |
Prepaid expenses and other current assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2023 |
|
December 31, 2022 |
| Prepaid Insurance |
$ |
28,442 |
|
|
$ |
117,315 |
|
| Prepaid Research and Development |
371,607 |
|
|
128,429 |
|
| Other |
88,901 |
|
|
97,325 |
|
| Total Prepaid Expenses and Other Current Assets |
$ |
488,950 |
|
|
$ |
343,069 |
|
|
| Schedule of accrued expenses |
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2023 |
|
December 31, 2022 |
| Payroll and Benefits |
$ |
860,050 |
|
|
$ |
1,312,443 |
|
| Professional Fees |
175,972 |
|
|
282,721 |
|
| Clinical Trials |
75,814 |
|
|
57,020 |
|
| Other |
69,886 |
|
|
183,750 |
|
| Total Accrued Expenses |
$ |
1,181,722 |
|
|
$ |
1,835,934 |
|
|
| Schedule of restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2023 |
|
December 31, 2022 |
| Cash and Cash Equivalents |
$ |
3,426,067 |
|
|
$ |
5,964,556 |
|
| Restricted Cash, Non-current |
4,185 |
|
|
49,260 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
3,430,252 |
|
|
$ |
6,013,816 |
|
|